NRIX is trading 5% up today at $19.81 as the stock continues its multi-week rally following a major multi-billion-dollar collaboration with Roche focused on blood cancer therapies.
- The partnership has fueled significant upside momentum, with shares previously surging 24% on the initial announcement of the deal.
- Multiple analyst firms have reiterated Buy and Outperform ratings, setting aggressive price targets ranging from the low-$30s to mid-$40s.
- Investor sentiment remains high as the collaboration validates the company's therapeutic platform and strengthens its long-term financial outlook.